|
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy
|
5R01CA208526-03
|
$472,047
|
$472,047
|
CUCINOTTA, FRANCIS
|
UNIVERSITY OF NEVADA LAS VEGAS
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-03
|
$506,533
|
$506,533
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral niche
|
5R01CA216054-02
|
$324,411
|
$324,411
|
HAYDEN GEPHART, MELANIE
|
STANFORD UNIVERSITY
|
|
(PQ1) Molecular circuit of multi-ciliogenesis regulates choroid plexus differentiation and tumor development
|
5R01CA220551-03
|
$315,193
|
$315,193
|
ZHAO, HAOTIAN
|
NEW YORK INST OF TECHNOLOGY
|
|
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS
|
1R01CA230712-01
|
$633,992
|
$633,992
|
JENKINS, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
$190,287
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal
|
5R01CA219667-02
|
$523,048
|
$523,048
|
DUMAN, JOSEPH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQB4) Stochastic Profiling of Functional Single-Cell States Within Solid Tumors
|
5R01CA194470-04
|
$446,627
|
$147,387
|
JANES, KEVIN
|
UNIVERSITY OF VIRGINIA
|
|
2D MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma
|
5R01CA203388-02
|
$413,689
|
$413,689
|
MAO, HUI
|
EMORY UNIVERSITY
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
|
2R44CA203351-03
|
$240,368
|
$240,368
|
MORGAN, LEE
|
DEKK-TEC, INC.
|
|
A 3D Model of the Perivascular Niche to Investigate Glioblastoma Invasion
|
1F31CA228317-01
|
$39,703
|
$39,703
|
WOLF, KAYLA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A CEST-MRI Reporter Gene for Image Guided Oncolytic Virotherapy
|
5R01CA203873-03
|
$391,481
|
$391,481
|
FARRAR, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A clones genomic stability as biomarker of its DNA-damage resilience
|
5K99CA215256-02
|
$166,644
|
$166,644
|
ANDOR, NOEMI
|
STANFORD UNIVERSITY
|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-03
|
$418,127
|
$418,127
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
A high content screen dissecting ciliogenesis and oncogenic Hedgehog signaling
|
5R01CA181231-03
|
$488,144
|
$244,072
|
REITER, JEREMY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A microfluidic blood-based test to monitor treatment response in glioblastoma
|
1R01CA226871-01A1
|
$454,640
|
$454,640
|
STOTT, SHANNON
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A new class of CSF-1R radioligands for monitoring glioblastoma progression and therapy
|
5R21CA205564-02
|
$171,060
|
$171,060
|
CHIN, FREDERICK
|
STANFORD UNIVERSITY
|
|
A novel microfluidic device to predict brain cancer prognosis and response to therapy
|
1R01CA216855-01A1
|
$496,519
|
$496,519
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors
|
5R01CA217956-02
|
$688,403
|
$688,403
|
BRADY-KALNAY, SUSANN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
|
5R01CA217179-02
|
$559,312
|
$559,312
|
MARKERT, JAMES
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
$546,873
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A SIGNALING PATHWAY SPECIFIC FOR ALKYLATION DAMAGE
|
1R01CA227001-01
|
$355,706
|
$355,706
|
MOSAMMAPARAST, NIMA
|
WASHINGTON UNIVERSITY
|
|
A Unique Class of Reductively Activated Oncology Drugs
|
5R01CA208669-02
|
$718,986
|
$359,493
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
|
A Vascularized, In Vitro, Organotropic Metastasis Model to Generate Dormant Micrometastases
|
5R21CA214299-02
|
$181,477
|
$45,369
|
SLATER, JOHN
|
UNIVERSITY OF DELAWARE
|
|
AAA Proteins, Their Functions and Related Diseases
|
ZIA BC 010600
|
$215,333
|
$215,333
|
Xia, Di
|
CCR (NCI)
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196 03152
|
$477,453
|
$23,873
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
$4,890
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
$1,114
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
$1,305
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
$154,335
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
|
2R44CA192427-04
|
$999,600
|
$999,600
|
OSTER, WOLFGANG
|
ONCOCEUTICS, INC.
|
|
Adaptive resistance to HIF1a inhibition in hypoxia
|
5R01CA207377-03
|
$352,269
|
$116,249
|
QIAN, ZHENG DAVID
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Administrative Supplement to Cancer Center Support Grant to Support Acquisition and Annotation of Biospecimens
|
3P30CA022453-36S5
|
$46,200
|
$1,848
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
Administrative Supplement: Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer
|
3R01CA195503-04S1
|
$55,777
|
$55,777
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Adult Brain Tumor Consortium (ABTC)
|
5UM1CA137443-09
|
$1,244,620
|
$1,244,620
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology
|
3R33CA206949-02S1
|
$94,996
|
$47,498
|
SPICER, TIMOTHY
|
SCRIPPS FLORIDA
|
|
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology
|
5R33CA206949-03
|
$460,385
|
$230,193
|
SPICER, TIMOTHY
|
SCRIPPS FLORIDA
|
|
Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma
|
1R01CA229784-01
|
$667,694
|
$667,694
|
CHAREST, ALAIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Advancing Treatments for Pediatric Craniopharyngioma (ATPC): Preliminary Assessment of the Cyst Fluid Inflammatory Milieu
|
5R03CA212800-02
|
$77,750
|
$77,750
|
HANKINSON, TODD
|
UNIVERSITY OF COLORADO DENVER
|
|
AIDS Malignancy Consortium (AMC)
|
3UM1CA121947-12S2
|
$25,000
|
$6,250
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Consortium (AMC)
|
5UM1CA121947-12
|
$23,766,226
|
$5,941,557
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
$97,489
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
$30,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
$242,214
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
An 18F PET/NIRF Smart Probe for Identifying, Grading, and Visualizing Astrocytic Gliomas
|
5F32CA213620-02
|
$61,174
|
$61,174
|
HETTIE, KENNETH
|
STANFORD UNIVERSITY
|
|
An immunoadhesin therapy for glioblastoma targeting CD97
|
1R43CA233386-01
|
$263,999
|
$263,999
|
WYCOFF, KEITH
|
PLANET BIOTECHNOLOGY, INC.
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$138,413
|
Barr, Frederic
|
CCR (NCI)
|
|
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice
|
1R01CA222804-01A1
|
$414,488
|
$414,488
|
GLORIOSO, JOSEPH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Assessing the Robustness of Radiogenomic Associations using Deep Neural Networks in Glioblastoma Multiforme
|
1F31CA221061-01A1
|
$38,615
|
$38,615
|
SMEDLEY, NOVA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Asymmetric cell division drives therapeutic resistance and self-renewal in glioblastoma
|
5R03CA215939-02
|
$79,250
|
$79,250
|
HITOMI, MASAHIRO
|
CLEVELAND CLINIC LERNER COM-CWRU
|
Total relevant funding to Brain for this search: $218,336,880
|